within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP55_SofosbuvirAndVelpatasvir;

model SofosbuvirAndVelpatasvir
  extends Pharmacolibrary.Drugs.ATC.J.J05AP55;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AP55</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sofosbuvir and velpatasvir is a fixed-dose combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection in adults and children. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, and velpatasvir is an NS5A inhibitor. The combination is approved and widely used globally as one of the standard regimens for pan-genotypic treatment of HCV.</p><h4>Pharmacokinetics</h4><p>PK parameters as reported in healthy adult volunteers following a single oral dose of the fixed-dose combination tablet (400 mg sofosbuvir/100 mg velpatasvir).</p><h4>References</h4><ol><li><p>Jonas, MM, et al., &amp; Schwarz, KB (2024). Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. <i>Journal of pediatric gastroenterology and nutrition</i> 78(6) 1342–1354. DOI:<a href=\"https://doi.org/10.1002/jpn3.12045\">10.1002/jpn3.12045</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38644678/\">https://pubmed.ncbi.nlm.nih.gov/38644678</a></p></li><li><p>Noskov, S, et al., &amp; Drai, R (2024). Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions. <i>Clinical pharmacology in drug development</i> 13(10) 1123–1129. DOI:<a href=\"https://doi.org/10.1002/cpdd.1435\">10.1002/cpdd.1435</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38881205/\">https://pubmed.ncbi.nlm.nih.gov/38881205</a></p></li><li><p>Brieva, T, et al., &amp; Rivero-Juarez, A (2017). Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. <i>Expert opinion on drug metabolism &amp; toxicology</i> 13(4) 483–490. DOI:<a href=\"https://doi.org/10.1080/17425255.2017.1292253\">10.1080/17425255.2017.1292253</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28165830/\">https://pubmed.ncbi.nlm.nih.gov/28165830</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end SofosbuvirAndVelpatasvir;
